eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | multiple myeloma |
| Symptom | C0238790|bone destruction |
| Sentences | 10 |
| PubMedID- 21548993 | Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma. |
| PubMedID- 26084129 | The impact of one fraction of 8 gy radiotherapy in palliative treatment of multiple myeloma patients with painful bone destructions. |
| PubMedID- 22941027 | bone destruction in myeloma is due to an increased activity of osteoclasts coupled with suppressed bone formation by osteoblasts. |
| PubMedID- 23420663 | bone destruction due to myeloma may occur in any area of the body. |
| PubMedID- 26174842 | N-terminal pro-c-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma. |
| PubMedID- 25322877 | Background: bone destruction is a feature of multiple myeloma, characterised by osteolytic bone destruction due to increased osteoclast activity and suppressed or absent osteoblast activity. |
| PubMedID- 24273897 | This review explores the current understanding of molecular pathways that promote myeloma progression and lead to bone destruction, with particular reference to the influence of interactions with the bone marrow microenvironment. |
| PubMedID- 20570621 | Tgf-beta-related mechanisms of bone destruction in multiple myeloma. |
| PubMedID- 19621390 | N-bps prevent bone destruction in myeloma by inhibiting the enzyme farnesyl pyrophosphate synthase in osteoclasts, thereby preventing the prenylation of small gtpase signaling proteins. |
| PubMedID- 22425892 | bone destruction is a hallmark of multiple myeloma and affects more than 80% of patients. |
Page: 1